A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

Taichi Takashina,Hajime Asahina,Satoshi Oizumi,Noriyuki Yamada,Masao Harada,Kei Takamura,Hiroshi Yokouchi,Toshiyuki Harada,Osamu Honjo,Takahiro Ogi,Naoto Morikawa,Ichiro Kinoshita,Ryoichi Honda,Kosuke Nakano,Kenya Kanazawa,Toraji Amano,Hirotoshi Dosaka-Akita,Hiroshi Isobe,Masaharu Nishimura

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

2018

Taichi Takashina
Hajime Asahina
Satoshi Oizumi
Noriyuki Yamada
Masao Harada
Kei Takamura
Hiroshi Yokouchi
Toshiyuki Harada
Osamu Honjo
Takahiro Ogi
Naoto Morikawa
Ichiro Kinoshita
Ryoichi Honda
Kosuke Nakano
Kenya Kanazawa
Toraji Amano
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura

Background This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR.

Keywords:

Pathology
Bevacizumab
Carboplatin
Pemetrexed
Phases of clinical research
Erlotinib
Cell
Oncology
Lung cancer
Maintenance therapy
Medicine
Internal medicine
Febrile neutropenia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations